Skip to main content
Top
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Oral presentation

O132. Treatment-as-prevention: stopping the epidemic of HIV

Author: B Williams

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Anti-retroviral drugs an reduce plasma HIV viral load by 3 to 4 orders of magnitude raising the possibility that treatment can be used not only to save individual lives but also to stop transmission. Modelling studies suggest that with the effective use of ART transmission of HIV could be eliminated within ten years and HIV infection within 40 years. The ides of using treatment as prevention has generated considerable interest and a certain amount of controversy. This presentation will describe the potential impact of treatment-as-prevention, compare the results with treatment-as-prophylaxis, and consider some of the key factors that could compromise the impact of this approach. These include coverage, compliance, the extent of viral load suppression, the reduction in transmission, the likelihood of virological failure, viral rebound and drug resistance. Possible ways of increasing the impact through targeting of the intervention will be discussed. Finally, some consideration will be given as to how best to test and possibly implement a programme of using treatment as prevention. …
Metadata
Title
O132. Treatment-as-prevention: stopping the epidemic of HIV
Author
B Williams
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-O13

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.